saquinavir (invirase) Report issue

Small molecule Approved FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Saquinavir (brand names Invirase and Fortovase) is an antiretroviral drug used together with other medications to treat or prevent HIV/AIDS. Saquinavir is an inhibitor of HIV protease. HIV protease is an enzyme required for the proteolytic cleavage of viral polyprotein precursors into individual functional proteins found in infectious HIV. Saquinavir is a peptide-like substrate analog that binds to the protease active site and inhibits the activity of the enzyme. Saquinavir inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature noninfectious virus particles. The most frequent adverse events with saquinavir in either formulation are mild gastrointestinal symptoms, including diarrhea, nausea, loose stools & abdominal discomfort. Invirase is better tolerated than Fortovase.   NCATS

Chemistry

  • SMILES: CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1
  • InChIKey: QWAXKHKRTORLEM-UGJKXSETSA-N
  • Mol. Mass: 670.86
  • ALogP: 3.09
  • ChEMBL Molecules:
    saquinavir  
    saquinavir mesylate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$2.6531

United States

$7.4141 - $9.8636
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

fortovase | invirase | ro-31-8959 | ro-318959000 | ro-318959003 | ro-31-8959-003 | saquinavir | saquinavir mesilate | saquinavir mesylate | saquinavir methanesulfonate | sequinavir | sqv

Organizations (47)

Research & Development (47)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (1)


 

HIV Infections (approved 1997)

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

AIDS-Associated Nephropathy (Phase 3)

Cardiovascular Diseases (Phase 4)

Directly Observed Therapy (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Drugs, Investigational (Phase 2/Phase 3)

Healthy Volunteers (Phase 4)

HIV-Associated Lipodystrophy Syndrome (Phase 4)

HIV Infections (Phase 4)

Pregnancy (Phase 1)

Pulmonary Arterial Hypertension (Early Phase 1)

Sarcoma (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 80
  • # of Trial Organizations: 47

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue